The present invention relates to the use of medium-chain length fatty acids of formula I, triglycerides of formula 2 (wherein n = 6 - 10), salts thereof, or mixtures thereof, in combination with gemcitabine and optionally erlotinib in the treatment of pancreatic cancer in human patients. Exemplary medium- chain length fatty acid/ triglyceride compounds include capric acid, sodium caprate, tricaprin, lauric acid, sodium laurate, and trilaurin.